Drugs
Eli Lilly and Ribozyme Pharmaceuticals Collaborate to Develop Novel Anti-Hepatitis C Treatment
Eli Lilly and Company, a global research-based pharmaceutical corporation, and Ribozyme Pharmaceuticals, Inc., a leader in ribozyme therapeutic development, have announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the development of a novel anti-Hepatitis C treatment, LY466700. This